References
- Meis PJ, Klebanoff M, Thom E, et al. Prevention of recurrent preterm delivery by 17 alpha-hydroxyprogesterone caproate. N Engl J med 2003;348:2379–85
- de Fonseca EB, Bittar RE, Carvalho MH, Zugaib M. Prophylactic administration of progesterone by vaginal suppository to reduce the incidence of spontaneous preterm birth in women at increased risk: a randomized placebo-controlled double-blind study. Am J Obstet Gynecol 2003;188:419–24
- Rouse DJ, Caritis SN, Peaceman AM, et al. A trial of 17 alpha-hydroxyprogesterone caproate to prevent prematurity in twins. N Engl J Med 2007;357:454–61
- Briery CM, Veillon EW, Klauser CK, et al. Progesterone does not prevent preterm births in women with twins. SMJ 2009;102:900–4
- Hassan SS, Romero R, Vidyadhari D, et al. Vaginal progesterone reduces the rate of preterm birth in women with a sonographic short cervix: a multicenter, randomized, double-blind, placebo-controlled trial. Ultrasound Obstet Gynecol 2011;38:18–31
- Romero R, Nicolaides K, Nicolaides K, et al. Vaginal progesterone in women with an asymptomatic sonographic short cervix in the midtrimester decreases preterm delivery and neonatal morbidity: a systematic review and metaanalysis of individual patient data. Am J Obstet Gynecol 2012;206:124.e1–18
- Briery CM, Veillon EW, Klauser CK, et al. Women with preterm premature rupture of the membranes do not benefit from weekly progesterone. Am J Obstet Gynecol 2011;204:54 e.1–5
- Berghella V. Progesterone and preterm birth prevention: translating clinical trials data into clinical practice. SMFM Clinical Guideline. Am J Obstet Gynecol 2012;206:376–85
- ACOG Practice Bulletin No. 127. Management of preterm labor. Obstet Gynecol 2012;119:1308–17
- Kramer MS, Papageorghiou A, Culhane JF, et al. Challenges in defining and classifying the preterm birth syndrome. Am J Obstet Gynecol 2012;206:108–12
- Facchinetti F, Paganelli S, Comitini G, et al. Cervical length changes during preterm cervical ripening: effects of 17-α-hydroxyprogesterone caproate. Am J Obstet Gynecol 2007;196:453.e1–4
- Rozenberg P, Chauveaud A, Deruelle P, et al. Prevention of preterm delivery after successful tocolysis in preterm labor by 17 alpha-hydroxyprogesterone caproate: a randomized controlled trial. Am J Obstet Gynecol 2012;206:206.e1–9
- Borna S, Sahabi N. Progesterone for maintenance tocolytic therapy after threatened preterm labour: a randomized controlled trial. Aust N Z J Obstet Gynecol 2008;48:58–63
- Sharami SH, Zahiri Z, Shakiba M, Milani F. Maintenance therapy by vaginal progesterone after threatened idiopathic preterm labor: a randomized placebo-controlled double-blind trial. Int J Fertil Steril 1020;4:45–50
- Peltier MR, Tee SC, Smulian JC. Effect of progesterone on proinflammatory cytokine production by monocytes stimulated with pathogens associated with preterm birth. Am J Reprod Immunol 2008;60:346–53
- Shields AD, Wright J, Paonessa DJ, et al. Progesterone modulation of inflammatory cytokine production in a fetoplacental artery explants model. Am J Obstet Gynecol 2005;193:1144–8
- Chollet J, Jozwiakowski M. Quality investigation of hydroxyprogesterone caproate active pharmaceutical ingredient and injection. Drug Dev Ind Pharm 2012;38:540–9
- Sibai BM, Istwan NB, Palmer B, Stanziano GJ. Pregnancy outcomes of women receiving compounded 17 α-hydroxyrogesterone caproate for prophylactic prevention of preterm birth 2004 to 2011. Am J Perinatol 2012;29:635–42